Piramal Pharma Limited has officially announced the successful completion of the acquisition of Kenalog® and its associated brands from Bristol-Myers Squibb Company. The transaction, executed through the company’s step-down wholly owned subsidiary, Piramal Critical Care B.V., marks a significant milestone in the organization’s growth strategy. This strategic move is set to bolster the company’s international footprint and enhance its specialized medical portfolio.
Strengthening the Hospital Generics Portfolio
Following the initial announcement on January 28, 2026, Piramal Pharma Limited has finalized the purchase of the commercial injectable product Kenalog®. This acquisition represents a tactical enhancement of the company’s Complex Hospital Generics portfolio, allowing for deeper penetration into high-value medical markets.
Strategic Market Expansion
The integration of the Kenalog® brand is expected to provide substantial long-term benefits by reinforcing the company’s presence across several key geographical regions. By absorbing these assets from Bristol-Myers Squibb Company, Piramal Pharma aims to leverage its existing infrastructure to accelerate growth in the United States, Europe, and the Asia Pacific regions. This deal aligns with the company’s broader mission to expand its reach and service capacity within the global healthcare sector.
Source: BSE
